Revive Therapeutics has announced that it is working on its first Phase I/II clinical study to evaluate oral psilocybin in the treatment of methamphetamine use disorder.
Heroic Hearts Project and Maya PBC are partnering to generate the largest structured dataset illustrating the health outcomes of psychedelic treatments for veterans and their family...
Small Pharma has received approval for an interaction study between the company’s lead N, N-dimethyltryptamine (DMT) candidate – SPL026 – and serotonin reuptake inhibitors (SSRIs).
The medical use of ketamine to alleviate symptoms of depression carries a low risk of addiction, suggests new research from the University of Geneva (UNIGE).
COMPASS Pathways has launched its multi-centre, doubleblind randomised controlled Phase 2 clinical trial investigating the efficacy of its proprietary formulation of synthetic psilocybin, COMP360, in people...
Enveric Biosciences has made advancements with its drug discovery and development progress targeting mental health indications and intellectual property (IP).
Cybin has confirmed it has received approval for its Phase 1/2a trial evaluating its proprietary deuterated psilocybin analogue for the treatment of Major Depressive Disorder (MDD).
A new study from Northwestern Medicine has identified for the first time how ketamine works so quickly, and how it might be adapted for use as...
UK-based Beckley Psytech and drug discovery company Lophora ApS will be researching New Clinical Entities (NCE’s) to bolster a pipeline of next-generation psychedelic medicines.
With growing scientific interest in the area of psychedelics, Duke University has launched the Center for Integrated Psychedelic Science (CIPS).